A Molecular Blueprint to Targeting ALK Gene Fusions in Glioblastoma.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 37260294.
- Also identified by DOI 10.1158/1078-0432.CCR-23-0472.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Glioblastoma (GBM) is a heterogeneous brain tumor entity from infancy through adulthood. ALK gene fusions enriched in congenital and infant GBM have emerged as druggable driver alterations. Understanding the molecular basis and prevalence of ALK gene rearrangements will help define patients with GBM who may benefit from ALK-targeted therapy. See related article by Blandin et al., p. 2651.
Medical subject headings
- Glioblastoma
- Brain Neoplasms